258 related articles for article (PubMed ID: 33203467)
1. The impact of mass drug administration on Schistosoma haematobium infection: what is required to achieve morbidity control and elimination?
Kura K; Hardwick RJ; Truscott JE; Toor J; Hollingsworth TD; Anderson RM
Parasit Vectors; 2020 Nov; 13(1):554. PubMed ID: 33203467
[TBL] [Abstract][Full Text] [Related]
2. Determining the optimal strategies to achieve elimination of transmission for Schistosoma mansoni.
Kura K; Ayabina D; Hollingsworth TD; Anderson RM
Parasit Vectors; 2022 Feb; 15(1):55. PubMed ID: 35164842
[TBL] [Abstract][Full Text] [Related]
3. Assessing the benefits of five years of different approaches to treatment of urogenital schistosomiasis: A SCORE project in Northern Mozambique.
Phillips AE; Gazzinelli-Guimaraes PH; Aurelio HO; Ferro J; Nala R; Clements M; King CH; Fenwick A; Fleming FM; Dhanani N
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006061. PubMed ID: 29220347
[TBL] [Abstract][Full Text] [Related]
4. How Does Treatment Coverage and Proportion Never Treated Influence the Success of Schistosoma mansoni Elimination as a Public Health Problem by 2030?
Kura K; Mutono N; Basáñez MG; Collyer BS; Coffeng LE; Thumbi SM; Anderson RM
Clin Infect Dis; 2024 Apr; 78(Supplement_2):S126-S130. PubMed ID: 38662698
[TBL] [Abstract][Full Text] [Related]
5. Achieving Elimination as a Public Health Problem for Schistosoma mansoni and S. haematobium: When Is Community-Wide Treatment Required?
Toor J; Rollinson D; Turner HC; Gouvras A; King CH; Medley GF; Hollingsworth TD; Anderson RM
J Infect Dis; 2020 Jun; 221(Suppl 5):S525-S530. PubMed ID: 31829414
[TBL] [Abstract][Full Text] [Related]
6. Schistosomiasis - Assessing Progress toward the 2020 and 2025 Global Goals.
Deol AK; Fleming FM; Calvo-Urbano B; Walker M; Bucumi V; Gnandou I; Tukahebwa EM; Jemu S; Mwingira UJ; Alkohlani A; Traoré M; Ruberanziza E; Touré S; Basáñez MG; French MD; Webster JP
N Engl J Med; 2019 Dec; 381(26):2519-2528. PubMed ID: 31881138
[TBL] [Abstract][Full Text] [Related]
7. Significantly reduced intensity of infection but persistent prevalence of schistosomiasis in a highly endemic region in Mali after repeated treatment.
Landouré A; Dembélé R; Goita S; Kané M; Tuinsma M; Sacko M; Toubali E; French MD; Keita AD; Fenwick A; Traoré MS; Zhang Y
PLoS Negl Trop Dis; 2012; 6(7):e1774. PubMed ID: 22860153
[TBL] [Abstract][Full Text] [Related]
8. Modelling control of Schistosoma haematobium infection: predictions of the long-term impact of mass drug administration in Africa.
Gurarie D; Yoon N; Li E; Ndeffo-Mbah M; Durham D; Phillips AE; Aurelio HO; Ferro J; Galvani AP; King CH
Parasit Vectors; 2015 Oct; 8():529. PubMed ID: 26489408
[TBL] [Abstract][Full Text] [Related]
9. Impact of Different Mass Drug Administration Strategies for Gaining and Sustaining Control of
King CH; Kittur N; Binder S; Campbell CH; N'Goran EK; Meite A; Utzinger J; Olsen A; Magnussen P; Kinung'hi S; Fenwick A; Phillips AE; Gazzinelli-Guimaraes PH; Dhanani N; Ferro J; Karanja DMS; Mwinzi PNM; Montgomery SP; Wiegand RE; Secor WE; Hamidou AA; Garba A; Colley DG
Am J Trop Med Hyg; 2020 Jul; 103(1_Suppl):14-23. PubMed ID: 32400356
[TBL] [Abstract][Full Text] [Related]
10. Determining post-treatment surveillance criteria for predicting the elimination of Schistosoma mansoni transmission.
Toor J; Truscott JE; Werkman M; Turner HC; Phillips AE; King CH; Medley GF; Anderson RM
Parasit Vectors; 2019 Sep; 12(1):437. PubMed ID: 31522690
[TBL] [Abstract][Full Text] [Related]
11. Six rounds of annual praziquantel treatment during a national helminth control program significantly reduced schistosome infection and morbidity levels in a cohort of schoolchildren in Zimbabwe.
Mduluza T; Jones C; Osakunor DNM; Lim R; Kuebel JK; Phiri I; Manangazira P; Tagwireyi P; Mutapi F
PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008388. PubMed ID: 32569278
[TBL] [Abstract][Full Text] [Related]
12. Modelling the impact of a Schistosoma mansoni vaccine and mass drug administration to achieve morbidity control and transmission elimination.
Kura K; Truscott JE; Toor J; Anderson RM
PLoS Negl Trop Dis; 2019 Jun; 13(6):e0007349. PubMed ID: 31166956
[TBL] [Abstract][Full Text] [Related]
13. The impact of single versus mixed Schistosoma haematobium and S. mansoni infections on morbidity profiles amongst school-children in Taveta, Kenya.
Gouvras AN; Kariuki C; Koukounari A; Norton AJ; Lange CN; Ireri E; Fenwick A; Mkoji GM; Webster JP
Acta Trop; 2013 Nov; 128(2):309-17. PubMed ID: 23313322
[TBL] [Abstract][Full Text] [Related]
14. Application of Schistosomiasis Consortium for Operational Research and Evaluation Study Findings to Refine Predictive Modeling of
King CH; Yoon N; Wang X; Lo NC; Alsallaq R; Ndeffo-Mbah M; Li E; Gurarie D
Am J Trop Med Hyg; 2020 Jul; 103(1_Suppl):97-104. PubMed ID: 32400357
[TBL] [Abstract][Full Text] [Related]
15. Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries.
Shen Y; King CH; Binder S; Zhang F; Whalen CC; Evan Secor W; Montgomery SP; Mwinzi PNM; Olsen A; Magnussen P; Kinung'hi S; Phillips AE; Nalá R; Ferro J; Aurelio HO; Fleming F; Garba A; Hamidou A; Fenwick A; Campbell CH; Colley DG
BMC Infect Dis; 2017 Sep; 17(1):652. PubMed ID: 28962552
[TBL] [Abstract][Full Text] [Related]
16. Two-year impact of single praziquantel treatment on infection in the national control programme on schistosomiasis in Burkina Faso.
Touré S; Zhang Y; Bosqué-Oliva E; Ky C; Ouedraogo A; Koukounari A; Gabrielli AF; Bertrand S; Webster JP; Fenwick A
Bull World Health Organ; 2008 Oct; 86(10):780-7, A. PubMed ID: 18949215
[TBL] [Abstract][Full Text] [Related]
17. Interrupting seasonal transmission of Schistosoma haematobium and control of soil-transmitted helminthiasis in northern and central Côte d'Ivoire: a SCORE study protocol.
Tian-Bi YT; Ouattara M; Knopp S; Coulibaly JT; Hürlimann E; Webster B; Allan F; Rollinson D; Meïté A; Diakité NR; Konan CK; N'Goran EK; Utzinger J
BMC Public Health; 2018 Jan; 18(1):186. PubMed ID: 29378542
[TBL] [Abstract][Full Text] [Related]
18. Intestinal schistosomiasis of Ijinga Island, north-western Tanzania: prevalence, intensity of infection, hepatosplenic morbidities and their associated factors.
Mueller A; Fuss A; Ziegler U; Kaatano GM; Mazigo HD
BMC Infect Dis; 2019 Oct; 19(1):832. PubMed ID: 31590657
[TBL] [Abstract][Full Text] [Related]
19. Maintaining Low Prevalence of Schistosoma mansoni: Modeling the Effect of Less Frequent Treatment.
Ayabina D; Kura K; Toor J; Graham M; Anderson RM; Hollingsworth TD
Clin Infect Dis; 2021 Jun; 72(Suppl 3):S140-S145. PubMed ID: 33909064
[TBL] [Abstract][Full Text] [Related]
20. Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and re-infection patterns.
Webster BL; Diaw OT; Seye MM; Faye DS; Stothard JR; Sousa-Figueiredo JC; Rollinson D
Acta Trop; 2013 Nov; 128(2):292-302. PubMed ID: 23022016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
